(Q34610495)

3 August 2017

1 reference

title

The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications (English)

1 reference

3 August 2017

0 references

Jean L Nakamura

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Expert Opinion on Therapeutic Targets

3 August 2017

published in

1 reference

3 August 2017

volume

11

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

463-472

1 reference

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Ligand-induced, receptor-mediated dimerization and activation of EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Systematic analysis of the epidermal growth factor receptor by mass spectrometry reveals stimulation-dependent multisite phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Proliferation of human malignant astrocytomas is dependent on Ras activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

21 January 2018

Ras protein signalling

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Akt signaling and cancer: surviving but not moving on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Mammalian TOR: a homeostatic ATP sensor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Regulation of translation initiation by FRAP/mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Structural alterations of the epidermal growth factor receptor gene in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Cisplatin-induced activation of the EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Cell biology. Lessons in rational drug design for protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.463

10.1517/14728222.11.4.463

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference